Efficacy of Parenteral Amantadine Therapy in the Treatment of Multiple System Atrophy With Predominant Parkinsonism

Clinical Neuropharmacology
Adit FriedbergIlana Schlesinger

Abstract

The aim of this study was to assess clinical response to a high-dose intravenous (IV) amantadine given for 5 consecutive days in patients with multiple system atrophy parkinsonism (MSA-P). Subjects with a diagnosis of MSA-P treated with IV amantadine were included. Patients' disease severity before and after therapy was evaluated using the Unified Multiple System Atrophy Rating Scale (UMSARS). Fourteen subjects (8 females) were included. In 10 subjects (71.4%), clinical improvement was noted. The UMSARS score after treatment decreased by 2 points (median [interquartile range, 0-3]) when compared with UMSARS score at baseline (P = 0.0020). Upon examining the walking parameter, a trend of improvement was shown (P = 0.0625) (range, 0-1 points). Neither specific demographic parameters nor occurrence of adverse effects was found to be a predictive factor for improvement. Adverse events were mild and transient except for one patient who experienced acute psychosis prompting treatment cessation, upon which psychosis resolved. Our preliminary data show that IV amantadine may be a safe and effective therapy in MSA-P. A double-blind placebo-controlled trial is needed to establish the true benefit of amantadine therapy.

References

Jan 1, 1988·Clinical Pharmacokinetics·F Y Aoki, D S Sitar
May 2, 1970·Lancet·C FieschiM E Tedone
Aug 1, 1994·Brain : a Journal of Neurology·G K WenningN P Quinn
Dec 30, 1998·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·S GilmanG Wenning
Jan 23, 1999·Journal of the Autonomic Nervous System·S GilmanG K Wenning
Jan 29, 1999·Archives of Neurology·P A HannaJ B Kirkpatrick
May 1, 1999·Journal of the Neurological Sciences·S GilmanG K Wenning
Sep 29, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Gregor K WenningUNKNOWN Multiple System Atrophy Study Group
Sep 15, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Felix GeserUNKNOWN European MSA Study Group
Oct 22, 2005·Clinical Neuropharmacology·Gregor K Wenning, UNKNOWN Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society
Nov 15, 2005·Journal of Neural Transmission·C ColosimoG K Wenning
Oct 6, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Martin KöllenspergerUNKNOWN EMSA-SG
Jan 15, 2015·The New England Journal of Medicine·Alessandra Fanciulli, Gregor K Wenning

❮ Previous
Next ❯

Citations

Apr 23, 2020·International Journal of Molecular Sciences·Lisa MészárosJürgen Winkler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.